The health care industry in India is flourishing day by day, providing innovative solutions to serve the needs of people combating diseases and illnesses. Undoubtedly, no other public healthcare intervention could be as simple, effective, and budget-friendly as vaccines are. To reduce the burden of vaccine-preventable diseases around the globe, various scientists and vaccine manufacturing companies are ardently working towards creating breakthrough innovations that could transform public health globally.

Dr. Krishna M. Ella (The founder and chairman of BBIL) in a quest for attaining innovative health care solutions targeting neglected infectious diseases, became a bio-entrepreneur enabling the birth of Bharat Biotech International Limited (BBIL) in the year 1996. To help patients around the world to lead a healthier life, BBIL is continuously creating effective vaccines and biotherapeutics for over 2 decades. Though based in India, BBIL exports its products to around 65 countries worldwide.

Some of the products manufactured by BBIL includes vaccines such as biohib, biopolio, HNVAC, JENVAC, revac-B mcf, revac-B+, rotovac, typbar, typbar TCV, comvac 3, comvac 4, comvac 5, and indirab. Biotherapeutics produced by BBIL encompasses regen-D 150, regen-D 60, biogit, SLVRGEN, and zelect.

The management understands the significance of R&D so that they evolve into a fertile breeding ground for new innovations and fresh ideas that focuses on eradicating the most challenging diseases around the world. BBIL owns around 160 patents for various life-saving therapeutics and vaccines. Now as a leading biotechnology company in India, BBIL excels in the worlds of biological product research and manufacturing to make health care therapeutics accessible to the general public.

FACTS TO KNOW

  • Bharat Biotech International Limited (BBIL) is recognized as one of the top 20 Most Innovative Companies in India by the Confederation of Indian Industry (CII) in the year 2016.
  • Research is conducted and prioritized for vaccine development targeting rotavirus, Chikungunya, malaria, liquid rabies, and Staphylococcus Aureus.
  • Manufacturing plants in BBL complies to the standards set by global regulators such as SFDA, UKMCA, KFDA, NRA, and WHO.
  • They have supplied around 3 billion vaccine doses globally.

“At Bharat Biotech, we do not see ourselves combating competitors. Instead, we are combating against region-specific neglected diseases”– Dr Krishna M. Ella

LEAVE A REPLY

Please enter your comment!
Please enter your name here